KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 112 filers reported holding KEROS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $851,451 | +43.8% | 26,708 | +81.3% | 0.00% | +50.0% |
| Q2 2023 | $592,012 | -22.7% | 14,734 | -17.9% | 0.00% | 0.0% |
| Q1 2023 | $765,995 | +3.4% | 17,939 | +16.3% | 0.00% | 0.0% |
| Q4 2022 | $740,805 | +36.9% | 15,427 | +7.2% | 0.00% | 0.0% |
| Q3 2022 | $541,000 | +40.2% | 14,390 | +2.9% | 0.00% | +100.0% |
| Q2 2022 | $386,000 | -60.3% | 13,986 | -21.9% | 0.00% | -50.0% |
| Q1 2022 | $973,000 | -7.1% | 17,900 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,047,000 | +47.9% | 17,900 | 0.0% | 0.00% | +100.0% |
| Q3 2021 | $708,000 | -6.8% | 17,900 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $760,000 | -31.0% | 17,900 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $1,102,000 | -13.7% | 17,900 | -1.1% | 0.00% | -33.3% |
| Q4 2020 | $1,277,000 | +195.6% | 18,100 | +61.6% | 0.00% | +200.0% |
| Q3 2020 | $432,000 | +2.9% | 11,200 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $420,000 | – | 11,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,382,641 | $85,102,000 | 10.19% |
| Consonance Capital Management LP | 890,209 | $54,792,000 | 5.84% |
| CHI Advisors LLC | 400,468 | $24,649,000 | 4.94% |
| Fairmount Funds Management LLC | 109,333 | $6,729,000 | 2.84% |
| VR Adviser, LLC | 372,306 | $22,915,000 | 2.49% |
| Opaleye Management Inc. | 157,500 | $9,694,000 | 1.42% |
| Darwin Global Management, Ltd. | 86,887 | $5,348,000 | 1.05% |
| Orbimed Advisors | 1,679,417 | $103,368,000 | 0.97% |
| Nantahala Capital Management | 460,372 | $28,336,000 | 0.83% |
| Eventide Asset Management | 427,414 | $26,307,000 | 0.39% |